Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824858 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of Food on LY3537982 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05824858 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants.
The verdict
NCT05824858, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 after meals and on an empty stomach. The study will also evaluate the safety and tolerability of LY3537982. Participants will stay in the research center during the study, which will last about one week, not including screening.
Interventions
- DRUG LY3537982
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2023-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05824858
The ClinicalTrials.gov registry entry for NCT05824858 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3537982 is the first listed.
NCT05824858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05824858 about?
NCT05824858 is a clinical study titled "A Study of the Effect of Food on LY3537982 in Healthy Participants". The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 after meals and on an empty stomach. The study will also evaluate the safety and tolerability of LY3537982. Participants will stay in the res...
What is the current status of trial NCT05824858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-04-12. Estimated completion is 2023-06-17.
What interventions are being tested in trial NCT05824858?
The interventions under investigation include: LY3537982 (DRUG).
Who is sponsoring clinical trial NCT05824858?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.